CG Oncology (NASDAQ: CGON) will participate in the AUA 2026 Annual Meeting in Washington, D.C., on May 15–18, 2026. The company will present first results from its CORE-008 Cohort CX Phase 2 trial in high-risk BCG-exposed and BCG-unresponsive NMIBC.
CG Oncology will also exhibit at booth #3051 and support CG-SUO-CTC NMIBC Research Fellowship presentations highlighting novel research in non-muscle invasive bladder cancer.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – CGON
+3.97%
+3.97%Session close to close
In the May 12 session, CGON gained 3.97%, reflecting a moderate positive market reaction.
This announcement highlights CG Oncology’s AUA presence and first CORE‑008 Cohort CX Phase 2 results...
Analysis
This announcement highlights CG Oncology’s AUA presence and first CORE‑008 Cohort CX Phase 2 results in high‑risk NMIBC, reinforcing focus on bladder cancer. Recent history shows larger moves tied to major clinical or financial updates, including a 29.26% reaction to accelerated PIVOT‑006 timelines and cash of $1,076.2M. Investors may watch upcoming detailed data, net loss trends around $60.2M quarterly, and progress toward the planned BLA submission.
Announced presentation at J.P. Morgan Healthcare Conference with webcast replay.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Shares have tended to react positively to substantial clinical and financial updates, with modest moves around routine conference appearances.
Recent Company History
Over the past six months, CG Oncology has combined frequent conference visibility with advancing bladder cancer programs. A Jan 9 update pulling forward PIVOT‑006 Phase 3 topline timing drove a 29.26% gain, while 2025 year-end results on Feb 27 and strong cash of $903.0M saw shares rise 4.79%. Routine investor conference announcements in January, February, and May generated smaller price changes, framing today’s AUA-focused presence as part of an ongoing visibility strategy.
"Phase 2 Trial evaluating intravesical combination therapy in High-Risk BCG-Exposed..."
Intravesical describes a medical treatment or procedure where a drug or therapy is placed directly into the bladder through a catheter rather than taken by mouth or injected into the bloodstream. For investors, it signals a focused delivery method that can increase local effectiveness and reduce whole‑body side effects, often affecting a product’s clinical value, patient convenience, regulatory path, and market niche — like watering a plant at its roots instead of spraying its leaves.
non-muscle invasive bladder cancermedical
"Patients with High-Risk BCG-Exposed or BCG-Unresponsive Non-Muscle Invasive Bladder Cancer"
A form of bladder cancer that is confined to the inner lining of the bladder and has not grown into the deeper muscle layer; think of it like a stain on wallpaper rather than damage to the wall’s studs. It matters to investors because it has different treatment, monitoring and recurrence patterns than deeper cancers, driving demand for repeated outpatient procedures, local therapies and diagnostic tests that affect revenue, trial design and pricing dynamics in healthcare markets.
bcg-unresponsivemedical
"High-Risk BCG-Exposed or BCG-Unresponsive Non-Muscle Invasive Bladder Cancer"
BCG-unresponsive describes a situation in which a patient’s bladder cancer does not shrink or returns despite receiving an adequate course of BCG, a common vaccine-based intravesical treatment used to stimulate the immune system in the bladder. For investors this matters because it defines a group of patients who need alternative therapies or procedures, shaping clinical trial eligibility, regulatory pathways, and the potential market for new drugs; think of it like weeds that resist the usual weed killer and require a different product.
spatial transcriptomic profilingmedical
"Spatial Transcriptomic Profiling of the Tumor Microenvironment in BCG-Unresponsive NMIBC..."
Spatial transcriptomic profiling maps which genes are active and where they are located within a tissue sample, combining gene activity measurements with their physical position much like a weather map shows temperatures across a city. Investors care because this method helps drug developers and diagnostics companies identify precise disease targets and biomarkers, which can speed up R&D, improve success rates, and create more valuable, differentiated products.
tumor microenvironmentmedical
"Spatial Transcriptomic Profiling of the Tumor Microenvironment in BCG-Unresponsive NMIBC..."
The tumor microenvironment is the immediate area surrounding a cancer cell, made up of nearby cells, blood vessels, and support structures that influence how the cancer grows and spreads. It functions like a bustling neighborhood that can either help or hinder the tumor’s development. For investors, understanding changes in this environment can signal the effectiveness of treatments and potential shifts in a cancer-related market.
gene therapiesmedical
"BCG-Unresponsive NMIBC Patients Treated with Novel Intravesical Gene Therapies"
Gene therapies are medical treatments that change or replace a person’s genetic instructions to fix or counteract a disease, using biological delivery methods to get the new material into cells — like repairing or swapping pages in a faulty instruction manual. They matter to investors because they can offer one-time or long-lasting cures with large market potential, but carry high development costs, regulatory scrutiny and manufacturing challenges that make outcomes binary and investment risky.
-First results from CORE-008 Cohort CX Phase 2 Trial evaluating intravesical combination therapy in High-Risk BCG-Exposed and BCG-Unresponsive patients to be presented-
-Visit CG Oncology at booth #3051-
DALLAS, May 11, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced its participation in the American Urological Association (AUA) 2026 Annual Meeting, taking place May 15–18, 2026, in Washington, D.C. CG Oncology will present first results from CORE-008 Cohort CX Phase 2 Trial evaluating intravesical combination therapy in High-Risk BCG-Exposed and BCG-Unresponsive patients and will be exhibiting at booth #3051. The AUA Annual Meeting is the largest global gathering of urologists and urologic professionals, showcasing the latest advances in urologic medicine, clinical research and patient care.
First Results from CORE-008 Cohort CX Title:Phase 2 Study of Intravesical Cretostimogene Grenadenorepvec with Gemcitabine in Patients with High-Risk BCG-Exposed or BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Additionally, the grant recipients of the annual CG-SUO-CTC NMIBC Research Fellowship will present their research at the SUO 2026 Annual Meeting at the AUA. This Fellowship is designed to support the development of outstanding clinical cancer research investigators who have demonstrated a commitment to improving the understanding and treatment of Non-Muscle Invasive Bladder Cancer (NMIBC). Details of the presentations are below:
Grant RecipientTaylor A. Goodstein, MD Presents: Spatial Transcriptomic Profiling of the Tumor Microenvironment in BCG-Unresponsive NMIBC Patients Treated with Novel Intravesical Gene Therapies May 16, 4:45 PM-4:50 PM ET
Grant Recipient Saum B. Ghodoussipour, MD Presents :Dynamic intra-tumor heterogeneity in non-muscle invasive bladder cancer May 16, 4:50 PM-4:55 PM ET
Attendees of AUA 2026 are encouraged to visit CG Oncology at booth #3051 to learn more about the company’s clinical development program and its commitment to advancing innovative therapies for patients with bladder cancer.
About CG Oncology CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. CG Oncology sees a world where urologic cancer patients may benefit from our innovative immunotherapies to live with dignity and have an enhanced quality of life. To learn more, please visit: www.cgoncology.com.
Contacts Media Sarah Connors Vice President, Communications and Patient Advocacy, CG Oncology sarah.connors@cgoncology.com
What is CG Oncology (NASDAQ: CGON) presenting at the AUA 2026 Annual Meeting?
CG Oncology will present first results from the CORE-008 Cohort CX Phase 2 trial in high-risk BCG-exposed and BCG-unresponsive NMIBC. According to CG Oncology, this study evaluates intravesical cretostimogene grenadenorepvec with gemcitabine in non-muscle invasive bladder cancer.
When and where will CG Oncology present CORE-008 Phase 2 data at AUA 2026?
CORE-008 data will be shared in a poster session on May 15, 2026, 3:30–5:30 PM ET and a podium presentation on May 16, 2026, 4:25–4:30 PM ET. According to CG Oncology, both sessions occur during the SUO 2026 Annual Meeting at AUA.
What is the CORE-008 Phase 2 trial that CG Oncology is discussing at AUA 2026?
CORE-008 is a Phase 2 study of intravesical cretostimogene grenadenorepvec with gemcitabine in high-risk BCG-exposed or BCG-unresponsive non-muscle invasive bladder cancer. According to CG Oncology, it assesses combination therapy delivered directly into the bladder (intravesical).
How is CG Oncology involved with NMIBC research fellowships presented at AUA 2026?
CG Oncology sponsors the annual CG-SUO-CTC NMIBC Research Fellowship, whose grant recipients present at SUO 2026. According to CG Oncology, the fellowship supports clinical cancer researchers focused on understanding and treating non-muscle invasive bladder cancer (NMIBC).
Which CG-SUO-CTC NMIBC fellowship projects linked to CG Oncology will be shown at AUA 2026?
Fellow Taylor A. Goodstein, MD will present on spatial transcriptomic profiling in BCG-unresponsive NMIBC treated with novel intravesical gene therapies, and Saum B. Ghodoussipour, MD will present on dynamic intra-tumor heterogeneity. According to CG Oncology, both talks occur May 16, 2026.
Where can attendees meet CG Oncology at the AUA 2026 Annual Meeting?
AUA 2026 attendees can visit CG Oncology at booth #3051. According to CG Oncology, visitors can learn more about the company’s clinical development program and its commitment to advancing innovative therapies for patients with non-muscle invasive bladder cancer.
